Buiten, R. A.

De Man, F. H. A. F.

Doelman, C.

Doggen, C. J. M.

Kant, G. D.

Kok, M. M.

Linssen, G. C. M.

Ploumen, E. H.

Sattar, N.

Stoel, M. G.

Von Birgelen, C.

Zocca, P.

English

University of Twente Research Information

Poster Session 7: Interventional Cardiology 4113P6517Three-year clinical outcome of patients with abnormal glucose metabolism treated with contemporarydrug-eluting stentsE.H. Ploumen1, R.A. Buiten1, M.M. Kok1, P. Zocca1, C.J.M. Doggen2, G.D. Kant3, M.G. Stoel1, F.H.A.F. De Man1, G.C.M. Linssen4, C. Doelman5,N. Sattar6, C. Von Birgelen11Medical Spectrum Twente, Thoraxcentre, Department of Cardiology, Enschede, Netherlands (The); 2University of Twente, Department of HealthTechnology and Services Research, Faculty BMS, Technical Medical Centre, Enschede, Netherlands (The); 3Medical Spectrum Twente,Department of Internal Medicine, Enschede, Netherlands (The); 4Ziekenhuisgroep Twente, Department of Cardiology, Almelo, Netherlands (The);5Medical Spectrum Twente, Department of Clinical Laboratory, Enschede, Netherlands (The); 6University of Glasgow, Institute of Cardiovascularand Medical Sciences, Glasgow, United KingdomFunding Acknowledgement: The present substudy received no additional funding. The BIO-RESORT trial was equally funded by Biotronik,Boston Scientific, and Medtronic.Background/Introduction: Patients with coronary artery disease thathave an abnormal glucose metabolism are known to have more extensiveand complex atherosclerotic coronary disease. In patients without previ-ously known diabetes, abnormal glucose metabolism was shown to be in-dependently associated with an up to four-fold higher event risk during thefirst year after percutaneous coronary intervention (PCI) with drug-elutingstents (DES).Purpose: To examine the 3-year clinical outcome after stenting withcontemporary DES in patients with abnormal glucose metabolism, ei-ther detected by oral glucose tolerance testing (OGTT) or by glycatedhaemoglobin A1c (HbA1c) and fasting plasma glucose.Methods: The present analysis is a local substudy of the BIO-RESORTrandomised trial. OGTT and HbA1c with fasting plasma glucose wereprospectively assessed in 988 trial participants without previously knowndiabetes. The main clinical endpoint was target vessel failure, a compositeof cardiac death, target vessel-related myocardial infarction or target vesselrevascularisation at 3-years.Results: In one out of three study participants (330/988), abnormal glu-cose metabolism was detected by either OGTT or HbA1c and fastingplasma glucose. Three-year follow up was available in 99.8% of these pa-tients. The rate of target vessel failure was significantly higher in patientswith abnormal glucose metabolism versus normoglycaemic patients (8.8%vs. 5.5%, p=0.044; Figure). This difference was driven by the incidence ofperiprocedural myocardial infarction that was higher in patients with abnor-mal glucose metabolism than in patients with normoglycaemia (4.5% vs.1.4%, p=0.002).Conclusion: Abnormal glucose metabolism was associated with a signif-icantly higher risk of target vessel failure at 3-years; this difference wasdriven by higher rates of periprocedural myocardial infarction.Target vessel failure at 3-yearsESC Congress 2019 together with World Congress of Cardiology31 August – 4 September 2019, Paris - FranceDownloaded from https://academic.oup.com/eurheartj/article/40/Supplement_1/ehz746.1107/5595617 by Universiteit Twente user on 25 August 2020

Three-year clinical outcome of patients with abnormal glucose metabolism treated with contemporary drug-eluting stents

https://doi.org/10.1093/eurheartj/ehz746.1107

Three-year clinical outcome of patients with abnormal glucose metabolism treated with contemporary drug-eluting stents

Abstract

Similar works

Full text

Available Versions

University of Twente Research Information